Life sciences insurance is commercial coverage built around the specific risks that biotech, pharmaceutical, and medical device companies face: product liability for investigational compounds, clinical trial exposure, intellectual property disputes, and regulatory actions. A standard policy written for a software company or a retail business won't touch these exposures. Getting the wrong coverage, or missing a line entirely, can leave a company financially exposed at exactly the moment it can least afford it.
This guide covers every coverage line life sciences companies need, the gaps that catch founders and CFOs off guard, how costs break down by stage, and what to look for in a broker who actually knows the space.
Why Life Sciences Companies Need Specialized Coverage
The risk profile of a biotech or medical device company is unlike almost any other industry. You may be developing a product that hasn't received FDA clearance yet. You may be running clinical trials involving human subjects. Your most valuable assets are often intangible: patents, proprietary compound data, and research pipelines. And your leadership team is making high-stakes decisions under intense regulatory scrutiny.
Standard commercial insurance doesn't account for any of that. A general liability policy written for a professional services firm typically excludes bodily injury arising from a product still in clinical development. That single exclusion could be catastrophic for a company running Phase II trials.
Life sciences insurance programs are built around the actual risk architecture of companies in this space, layering coverage across product risk, clinical exposure, professional liability, executive decisions, cyber threats, and operational continuity. The goal is a program with no gaps between policies, not just a collection of generic lines.
Who needs life sciences insurance? Biotech companies, pharmaceutical manufacturers, medical device companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), diagnostics and laboratory services firms, digital health platforms, Software as a Medical Device (SaMD) companies, and compounding pharmacies all require specialty coverage that general commercial policies do not provide.
Core Coverage Lines for Life Sciences Companies
Product Liability Insurance
Product liability is the foundation of any life sciences insurance program. It covers bodily injury or property damage caused by a product you manufacture, distribute, or sell: devices that malfunction, investigational drugs, biologics, and commercial compounds.
The critical detail: coverage must extend to products still in development, not just those already on the market. Many standard product liability policies contain a pre-commercial product exclusion that strips coverage for investigational compounds. If you're in clinical development, verify explicitly that your policy covers investigational products. This isn't a technicality. It's the difference between having coverage and having a gap that could end the company.
Commercial-stage companies also need to evaluate limits carefully relative to product revenue, distribution geography, and the severity of potential adverse events. A single product liability claim in the medical device space can exceed $10 million in costs.
Clinical Trial Liability Insurance
Clinical trial liability, sometimes called clinical trial insurance or study-specific coverage, covers bodily injury to trial participants arising from the conduct of a clinical study. This is distinct from general product liability. It typically covers adverse events, protocol deviations, and injuries that occur during the trial period across Phase I, Phase II, and Phase III studies.
Most institutional review boards (IRBs) and contract research organizations (CROs) require proof of clinical trial insurance before a study can begin. For companies running foreign clinical trials, coverage must be confirmed in each jurisdiction where the study is conducted. This is not optional coverage. It's a contractual requirement for operating.
Watch for the clinical-to-commercial gap. Clinical trial coverage typically ends when a trial concludes. Product liability for a commercial product typically begins at launch. The window between trial completion and FDA approval, when post-trial adverse events can still surface, is a known coverage gap. Your broker must explicitly address this transition in your policy structure.
Directors and Officers (D&O) Insurance
Life sciences companies carry above-average D&O exposure. FDA investigations, investor disputes after a failed trial, shareholder actions following a stock drop, and securities litigation after an IPO are real scenarios, not hypotheticals. D&O insurance protects the personal assets of your executives and board members when they're sued for decisions made in their capacity as officers or directors.
D&O is not a "later" purchase. Investors often require minimum D&O limits as a condition of a funding round, and the exposure is present from the moment you have a board. Limits should be reviewed after each significant financing event, when new institutional investors join the board, and before any IPO filing.
Professional Liability / Errors and Omissions (E&O) Insurance
For life sciences companies that provide services such as contract research, lab testing, regulatory consulting, or medical device software, professional liability (E&O) covers claims that your services caused financial loss or harm due to a mistake, omission, or failure to perform.
Technology E&O insurance is especially relevant for medical device companies and Software as a Medical Device (SaMD) companies whose products include software components, embedded firmware, or cloud-connected features. If your device collects patient data, processes diagnostic information, or connects to a hospital network, Tech E&O belongs in your program alongside product liability, not as a replacement for it.
Cyber Liability Insurance
Life sciences companies are high-value targets for cybercriminals. Clinical trial data, patient records, proprietary research, and manufacturing IP are all attractive. A ransomware attack that takes down a lab management system or delays a trial timeline can cause material financial harm well beyond the direct cost of the breach itself.
Cyber liability covers first-party costs like breach response, notification, and business interruption, as well as third-party liability if patient or partner data is compromised. Given evolving FDA guidance on medical device cybersecurity and the layering of state privacy laws on top of HIPAA, cyber limits should be sized to reflect actual data volume and regulatory exposure, not purchased at minimums.
General Liability Insurance
General liability covers third-party bodily injury and property damage connected to your operations: a visitor injured at your facility, damage to a client's property during an on-site installation, or advertising injury claims. For life sciences companies, general liability works alongside product liability rather than replacing it. The two policies cover different types of claims, and gaps between them are common when policies aren't structured carefully together.
Commercial Property Insurance
If you operate a lab, manufacturing facility, cleanroom, or research space, commercial property coverage protects your physical assets: equipment, inventory, raw materials, and the building itself if you own it. Biotech companies with specialized equipment such as bioreactors, centrifuges, cold storage systems, precision instruments, and vivaria face replacement costs that standard property policies frequently undervalue.
Your policy should account for the full replacement cost of specialized lab equipment, spoilage and contamination coverage for perishable biologics, and change-in-controlled-environment protection for cleanrooms. Biocontamination insurance is a separate endorsement that many lab operators overlook until a claim makes it relevant.
Workers' Compensation Insurance
Workers' comp is required in virtually every state if you have employees. For life sciences companies, the relevant risk categories include lab workers exposed to hazardous materials or biological agents, field service technicians who install or maintain medical devices, and manufacturing employees working with ignitable liquids or chemical compounds. Classification codes should accurately reflect actual job functions. Misclassification affects both coverage adequacy and cost.
Key Person Insurance
Biotech and medical device companies are often built around a small number of scientists, researchers, or executives whose departure would materially affect the company's ability to operate. Key person insurance provides a death or disability benefit to the company if a named individual can no longer work, giving the business financial runway to recruit a replacement or manage the transition. Investors and lenders often require key person coverage for the founding scientist or chief medical officer, particularly at pre-revenue and early-commercial stages.
Coverage by Company Type
Biotech Company Insurance
Biotech insurance programs center on clinical trial liability and product liability for investigational compounds from the earliest stages. D&O is necessary as soon as a board is formed. Cyber liability is essential even pre-revenue because proprietary compound data and trial results are prime targets. As programs advance to Phase III and commercial approval, product recall insurance and supply chain disruption coverage become material additions.
Medical Device Insurance
Medical device insurance requires product liability that covers device malfunction and failure modes, including latent injury liability for harm that surfaces years after use. Companies with connected devices, diagnostic software, or data-processing firmware need Tech E&O alongside product liability. The two coverages address different failure modes and should not be conflated. Field service technicians servicing installed equipment add a workers' comp and GL exposure that must be classified correctly.
CRO and CDMO Insurance
Contract research organizations and contract development and manufacturing organizations carry professional liability exposure that is distinct from their sponsor clients' product liability. A CRO's errors in trial design, protocol execution, or data management can result in significant third-party claims. Professional liability (E&O), specifically worded for research services, is the core coverage line, alongside clinical trial liability and cyber to protect trial data and participant records.
Digital Health and SaMD Insurance
Software as a Medical Device (SaMD) companies and digital health platforms operate in a regulatory environment that sits between medical device and technology, and the insurance program needs to reflect that. Tech E&O, cyber liability, and product liability are all relevant. FDA cyber guidance for software-based devices is maturing rapidly, and coverage limits for cyber should be sized to match both regulatory exposure and patient data volume.
Coverage Gaps That Catch Life Sciences Companies Off Guard
The Pre-Commercial Product Exclusion
Many product liability policies exclude products that haven't received regulatory clearance. If you're in Phase I or Phase II trials and your policy contains this exclusion, you have a significant uninsured exposure. Always confirm that investigational products are explicitly covered, and get that confirmation in writing from the carrier, not just the broker.
Recall Expense Coverage
If a medical device is recalled, voluntarily or under an FDA order, the costs of notifying customers, retrieving products, and managing the logistics can be substantial. Standard product liability policies typically do not cover those expenses. A product recall endorsement or standalone recall policy addresses this directly. Without it, a recall is an out-of-pocket operational crisis on top of the underlying product event.
Intellectual Property Disputes
IP litigation is common in life sciences. Patent infringement claims can come from competitors, patent assertion entities, or former partners. Standard commercial policies don't cover IP defense costs. Some companies address this through specialized IP insurance, though it is a complex and expensive line to place. The earlier a company begins building a defensible IP posture, the better positioned it is if litigation arises.
Pollution and Contamination Liability
Labs that handle hazardous chemicals, biological agents, or radioactive materials face environmental liability exposure that standard general liability policies exclude. Depending on what your facility handles and how waste is managed, environmental or pollution liability coverage may be necessary to address regulatory enforcement, cleanup costs, and third-party bodily injury arising from contamination.
The Clinical-to-Commercial Gap
As noted above, the window between trial completion and commercial approval is a known gap where neither clinical trial coverage nor commercial product liability is clearly in force. Post-trial adverse events can surface during FDA review periods. This gap must be addressed structurally in policy language. It cannot be assumed away.
Cleanroom Contamination and Biocontamination
A contamination event in a GMP manufacturing facility or cleanroom can halt production, destroy inventory, and trigger regulatory action. Standard property policies often exclude biological contamination or undervalue the business interruption costs of a production shutdown. Biocontamination insurance and change-in-controlled-environment endorsements are separate lines that many early-stage companies add only after a near-miss or an underwriter flags the gap at renewal.
How Life Sciences Insurance Needs Change by Funding Stage
| Stage | Typical Coverage Requirements | Key Triggers |
|---|---|---|
| Pre-Seed / Seed | D&O, General Liability, Cyber, Professional Liability (if services are provided) | Board formation, first investor; IRB application |
| Series A | Add Clinical Trial Liability (Phase I), increase D&O limits, Product Liability (investigational) | IND filing, first-in-human study, institutional investor board seats |
| Series B / C | Add Product Recall, expand Property, increase all limits; Key Person coverage | Phase II/III trials, manufacturing buildout, hospital and CRO partnerships requiring COI |
| Pre-Commercial | Bridge clinical and product liability; add Supply Chain Disruption, Commercial Property at full replacement cost | FDA submission; post-trial adverse event window; manufacturing at scale |
| Commercial Stage | Full program: Product Liability at commercial limits, Recall, Workers' Comp across all states, Cyber at patient-data volume, D&O updated for public or late-stage private company | Launch, distribution agreements, revenue recognition, multi-state or international expansion |
Multi-state or international expansion adds another layer of complexity. Coverage must be confirmed in each jurisdiction where you operate, distribute, or run trials. Foreign clinical trial insurance has its own requirements and cannot be assumed to flow from a domestic policy.
How Much Does Life Sciences Insurance Cost?
Life sciences insurance costs vary significantly based on company stage, product type, clinical activity, funding, and prior claims history. The ranges below are general market estimates drawn from publicly available industry sources, not Aiden quotes, and they are starting points only. Actual premiums depend on the specific risk profile underwriters see, and a coverage analysis is the only way to get a figure specific to your business.
Early-stage biotech (pre-revenue, no active IND): A basic package including D&O, general liability, and cyber typically starts in the $15,000 to $35,000 annual range. Once clinical trial liability is added, premiums increase based on trial phase, number of sites, and indication.
Clinical-stage companies (Phase I to III active): Clinical trial liability premiums are sized to the study. Phase I first-in-human studies, rare disease indications, and oncology trials all carry different risk profiles. A mid-stage company with active trials across multiple lines may spend $50,000 to $200,000+ annually across a full program.
Commercial-stage medical device or pharmaceutical companies: At commercial scale, product liability limits must reflect revenue and distribution geography. Companies with global distribution and established revenue may carry insurance programs in the $250,000 to $1M+ range across all lines.
What drives life sciences insurance costs? Underwriters look at indication and product type, phase of development, number of trial sites and jurisdictions, prior adverse events, claims history, IP position, regulatory status, revenue and funding, and quality systems (GMP, ISO certifications). A clean regulatory history, robust QMS documentation, and a proactive risk management posture all reduce premiums.
Certificate of Insurance (COI): What Partners, CROs, and Hospitals Require
A Certificate of Insurance (COI) is a summary document proving your coverage is in force. In life sciences, COI requirements are embedded in virtually every significant contract: CRO master service agreements, hospital partnership agreements, investor term sheets, and FDA facility agreements.
Common COI requirements from life sciences partners include: naming the partner as an additional insured, confirming primary and noncontributory status, waiver of subrogation, and minimum coverage limits by line. Deals are frequently delayed, sometimes significantly, because a company discovers mid-negotiation that its current policy doesn't meet a partner's COI requirements. Resolving a coverage gap at contract execution takes longer than building the right program upfront.
Before entering any significant partnership, confirm your COI will satisfy the likely requirements. A specialty life sciences broker should review your program against the standard language in IRB agreements, hospital contracts, and CRO MSAs, not wait for the other party's legal team to flag the gap.
What to Look for in a Life Sciences Insurance Broker
Life sciences is a specialty. A generalist broker who primarily serves retail or construction clients won't know the clinical trials liability market, won't understand FDA regulatory exposure, and may not have relationships with carriers that actually write life sciences programs. The carriers that specialize in life sciences, and the underwriters within those carriers, look at risk very differently from standard commercial markets.
When evaluating a broker, ask specifically about their experience placing coverage for companies at your stage and in your sub-sector: biotech, diagnostics, medical devices, contract research, digital health, or SaMD. Ask how they handle the gap between clinical trials and commercial product coverage. Ask whether they perform a coverage gap analysis before binding. Ask which life sciences carriers they have direct access to and which lines they wholesale to a third party.
Aiden pairs an AI risk engine with licensed brokers. The AI analyzes 140+ data vectors to build a risk profile specific to your business, a licensed broker reviews that analysis and places coverage from a panel of 100+ carriers, and your risk profile is watched year-round so changes surface between renewals instead of at them. The intake takes about 5 minutes, with no 40-page applications and no multi-week wait. Get a quote at aidenrisk.com.
Key Takeaways
- Product liability for life sciences must explicitly cover investigational and pre-commercial products, not just market-ready ones. Confirm in writing.
- Clinical trial liability is a separate, required line for any company running human studies. IRBs and CROs require proof before a study begins.
- D&O insurance is not a post-funding purchase. Executives and board members are exposed from day one, and investors require it before closing rounds.
- Technology E&O matters if your device or platform includes software, connectivity, or data processing. Product liability alone does not cover software failure modes.
- The gap between clinical trial coverage and commercial product liability is real. Structure policies to explicitly cover the post-trial, pre-approval window.
- Product recall insurance covers costs that standard product liability does not: customer notification, retrieval logistics, and administrative management of a recall.
- Cyber liability is essential even pre-revenue. Proprietary research data, compound information, and participant records are high-value targets regardless of commercial stage.
- Key person insurance protects the company if a critical scientist or executive can no longer work. Investors and lenders increasingly require it.
- Your broker's life sciences experience matters as much as the policy itself. Specialty carriers, underwriting relationships, and knowledge of standard COI requirements are not fungible skills.
FAQs
What is life sciences insurance?
Life sciences insurance is a set of commercial coverage lines tailored to the specific risks of biotech, pharmaceutical, and medical device companies. It typically includes product liability for investigational and commercial products, clinical trial liability, directors and officers (D&O) insurance, professional liability (E&O), cyber liability, and general liability. Standard commercial policies are not designed for these exposures. The exclusions alone can create catastrophic gaps for companies in clinical development.
Do biotech companies in clinical trials need separate insurance from product liability?
Yes. Clinical trial liability and product liability are distinct coverages. Clinical trial liability covers bodily injury to participants during a study, including adverse events and protocol deviations. Product liability covers harm caused by a product after it is manufactured or distributed. Companies actively running trials need both, and a specialty broker must structure the policies to prevent a gap between them.
What insurance do biotech startups need before Series A?
Pre-Series A biotech startups typically need directors and officers (D&O) insurance, general liability, cyber liability, and clinical trial liability if any human studies are planned. Professional liability (E&O) applies if the company provides research services. D&O is not a "later" purchase. Investors often require it before a funding round closes, and personal assets of executives and board members are exposed from day one.
When should a life sciences company increase its D&O limits?
D&O limits should be reviewed after any significant funding round, when new institutional board members join, before an IPO, and when the company faces FDA regulatory scrutiny. Investors at Series A and beyond typically specify minimum D&O limits as a condition of investment. These minimums should be treated as a floor, not a target.
What does clinical trial liability insurance cover?
Clinical trial liability covers bodily injury to trial participants arising from the conduct of a clinical study, including adverse events and protocol deviations across Phase I, Phase II, and Phase III. Most IRBs and CROs require proof before a study begins. It does not cover product liability claims after the trial ends. That gap must be addressed separately in your policy structure.
Is cyber insurance necessary for a pre-commercial biotech company?
Yes. Even pre-commercial biotech companies hold highly valuable data: proprietary compound data, clinical trial results, research pipelines, and partner agreements. A ransomware attack can delay trials, expose confidential IP, and trigger notification obligations if any human subject data is involved. Cyber liability should be part of any life sciences insurance program regardless of commercial stage.
Does medical device insurance need to cover software components?
Yes. Medical device companies whose products include software components, embedded firmware, or cloud-connected features need technology E&O (Tech E&O) in addition to product liability. This is especially true for Software as a Medical Device (SaMD) companies and any device that collects patient data, processes diagnostic information, or connects to a hospital network. The two coverages address different failure modes and are not interchangeable.
What is the coverage gap between clinical trials and product liability?
Clinical trial coverage typically ends when a trial concludes. Product liability for a commercial product typically begins at launch. The window between trial completion and FDA approval, when post-trial adverse events can still surface, is a known gap. Policies must be structured to explicitly cover this transition. Ask your broker to show you the exact policy language addressing this period before binding.
How do I know if my policy covers a product recall?
Review your product liability policy for a recall expense endorsement or standalone recall coverage. If neither is present, your policy does not cover the administrative and logistical costs of a voluntary or FDA-ordered recall, including customer notification, product retrieval, and logistics management. Ask your broker to confirm recall coverage explicitly before renewal.
What is key person insurance and why do life sciences investors require it?
Key person insurance pays a benefit to the company if a named individual, typically a founding scientist, chief medical officer, or other critical executive, dies or becomes permanently disabled. Investors require it because the company's value is often closely tied to specific individuals, and the policy provides financial continuity if that person can no longer work. It is increasingly required at pre-revenue and Series A stages.
What do CROs and hospitals require on a Certificate of Insurance (COI)?
Common COI requirements include naming the partner as an additional insured, confirming primary and noncontributory status, waiver of subrogation, and minimum coverage limits by line (often $1M to $5M per occurrence for product liability and $5M to $10M aggregate). Reviewing your program against likely COI requirements before entering negotiations prevents delays at contract execution.